Ian Sanderson - Catabasis Pharmaceuticals CFO, Treasurer
CFO
Mr. Ian C. Sanderson is the Chief Financial Officer at Catabasis Pharmaceuticals Inc. Mr. Sanderson joined Catabasis in 2013 as chief financial officer. Mr. Sanderson has more than 25 years of experience in life sciences investment research investment banking and financial operations. Prior to Catabasis Mr. Sanderson was a senior advisor at JSBPartners L.P. Prior to JSBPartners Mr. Sanderson was a managing director at Cowen and Company LLC where he spent 20 years as an equity research analyst covering the specialty pharmaceuticals pharmaceuticals and medical technology sectors. Mr. Sanderson began his life sciences career in healthcare investment banking at Cowen and Company and Houlihan Lokey Howard and Zukin and in financial operations at U.S. Surgical Corporation since 2014.
| Age | 53 |
| Tenure | 10 years |
| Professional Marks | MBA |
| Phone | 617 349 1971 |
| Web | http://www.catabasis.com |
Catabasis Pharmaceuticals Management Efficiency
The company has return on total asset (ROA) of (20.32) % which means that it has lost $20.32 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (210.26) %, meaning that it created substantial loss on money invested by shareholders. Catabasis Pharmaceuticals' management efficiency ratios could be used to measure how well Catabasis Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities.The company currently holds 713 K in liabilities with Debt to Equity (D/E) ratio of 0.01, which may suggest the company is not taking enough advantage from borrowing. Catabasis Pharmaceuticals has a current ratio of 34.42, suggesting that it is liquid enough and is able to pay its financial obligations when due. Debt can assist Catabasis Pharmaceuticals until it has trouble settling it off, either with new capital or with free cash flow. So, Catabasis Pharmaceuticals' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Catabasis Pharmaceuticals sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Catabasis to invest in growth at high rates of return. When we think about Catabasis Pharmaceuticals' use of debt, we should always consider it together with cash and equity.
Similar Executives
| Found 6 records | CFO Age | ||
| Raul Francos | Corporacion America Airports | 72 | |
| Michael CFA | United Airlines Holdings | 44 | |
| Gerald Laderman | United Airlines Holdings | 66 | |
| David Saperstein | TFI International | N/A | |
| Craig Conti | Verra Mobility Corp | 45 | |
| Andrew McBride | Verra Mobility Corp | 35 | |
Management Performance
| Return On Equity | -210.26 | |||
| Return On Asset | -20.32 |
Catabasis Pharmaceuticals Leadership Team
Elected by the shareholders, the Catabasis Pharmaceuticals' board of directors comprises two types of representatives: Catabasis Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Catabasis. The board's role is to monitor Catabasis Pharmaceuticals' management team and ensure that shareholders' interests are well served. Catabasis Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Catabasis Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Jean George, Director | ||
| Angelika Fretzen, Senior Vice President - Product Development | ||
| Gregg Lapointe, Director | ||
| Rick Modi, Chief Business Officer | ||
| Joanne Donovan, Chief Medical Officer | ||
| Deirdre Cunnane, Senior Vice President General Counsel | ||
| Michael Jirousek, Co-Founder and Member of Scientific Advisory Board | ||
| Michael Kishbauch, Director | ||
| Edward Hibben, Chief Business Officer | ||
| Joanne Beck, Director | ||
| Ian Sanderson, CFO, Treasurer | ||
| Burt Adelman, Director | ||
| Deirdre JD, Sr. VP and General Counsel | ||
| Kenneth Bate, Director | ||
| Hugh Cole, Director | ||
| Jill Milne, Co-Founder, CEO and President and Director | ||
| Andrea Matthews, IR Contact Officer | ||
| Nicholas Galakatos, Director | ||
| Ron Laufer, Director | ||
| Michael Ross, Chairman of the Board | ||
| Andrew Nichols, Sr. VP of Research | ||
| Ted Hibben, Sr. VP of Corporate Devel. |
Catabasis Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Catabasis Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -210.26 | |||
| Return On Asset | -20.32 | |||
| Current Valuation | 58.17 M | |||
| Shares Outstanding | 76.95 M | |||
| Shares Owned By Insiders | 0.03 % | |||
| Shares Owned By Institutions | 54.77 % | |||
| Number Of Shares Shorted | 96.27 K | |||
| Price To Earning | (1.24) X | |||
| Price To Book | 0.98 X | |||
| Price To Sales | 258.49 X |
Pair Trading with Catabasis Pharmaceuticals
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Catabasis Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Catabasis Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.The ability to find closely correlated positions to Hartford Financial could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Hartford Financial when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Hartford Financial - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Hartford Financial Services to buy it.
The correlation of Hartford Financial is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Hartford Financial moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Hartford Financial moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Hartford Financial can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in estimate. You can also try the ETF Categories module to list of ETF categories grouped based on various criteria, such as the investment strategy or type of investments.
Other Consideration for investing in Catabasis Stock
If you are still planning to invest in Catabasis Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Catabasis Pharmaceuticals' history and understand the potential risks before investing.
| Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| Transaction History View history of all your transactions and understand their impact on performance | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments |